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Interleukin-l (IL-1) represents a family of polypeptides with a wide range of biological
activities. cDNA from two gene products has been cloned; there are probably more. The human
IL-I family plays an important role in the pathogenesis of many diseases and functions as a key
mediator of host response to various infectious, inflammatory, neoplastic, and immunologic
challenges. Recombinant mouse (pl 5) and recombinant human (pl 7) IL-Is are being used to
confirm the multiple biological properties of IL-Is. Some IL-1 biological activities seem to be
involved with mechanisms of host tumor killing. Incubating purified or recombinant human IL-I
with human peripheral blood mononuclearcells in the presenceofIL-2 orinterferon-alpha results
in a synergistic enhancement of certain tumor cells. More recent results indicate that IL-1
exhibits direct cytotoxicity for tumor cells in vitro. The peripheral blood mononuclear cells of
patients with tumors demonstrate decreased production of IL-I when challenged with endotoxin
and show a comparable decrease in natural killer activity; adding exogenous IL-1 reverses this
defect in these patients. However, induction of hepatic acute-phase proteins such as serum
amyloid A serves as a negative feedback since the amyloid protein suppresses natural killer
activity. Moreover, natural killer cell activity in the presence of IL-1 or interferon-alpha is
suppressed by incubating temperatures of 390C. This effect is not reversed by inhibitors of
prostaglandin synthesis. IL-1 is clearly important to host defense against malignancy, but some
aspects of IL-I biology seem to exert a contrary influence.
INTRODUCTION
Microbial invasion, injury, immunological reactions, neoplastic changes, and
inflammatory processes continually challenge the host's ability to survive. The host,
faced with either exogenous or endogenous insults, responds with a series ofdramatic
changes, most of which are, for the most part, directed at elimination. They are
characterized by alterations in metabolic, endocrinologic, neurologic, and immuno-
logic functions. The full spectrum of these acute phase changes includes increases in
the synthesis of hepatic acute-phase proteins, leukocytosis primarily of circulating
immature neutrophils, decreased plasma iron and zinc levels, negative nitrogen
balance, and various endocrinologic changes. Neurologic changes are fever, increased
lassitude or sleep, and decreased appetite. Aspects of altered immunoregulation are
inconsistent; polyclonal B-cell activation usually occurs but increased suppressor cells
and anergy can also be present. Hypergammaglobulinemia and increased hepatic
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proteins result in elevated erythrocyte sedimentation rates. Although the most florid
presentation of the acute-phase response is observed in patients with bacterial
infections, burns, or multiple injuries, clinicians encounter acute-phase changes in
patients with occult infections or chronic illnesses. The presence of acute-phase
changes can also serve as a silent indicator oflocal disease and some cancers.
The various acute-phase responses have the outstanding characteristic of being a
generalized host reaction irrespectiveofthe localized or systemic natureofthe inciting
disease. They can be used for diagnosis or monitoring the progression of disease.
Perhaps the most fundamental event in the initiation of the response is the production
of a mediator called interleukin-1 (IL-1), a family of polypeptides which directly or
indirectly induces both laboratory and clinical aspects ofthe acute-phase response [1].
IL-I is produced primarily from phagocytic cells, enters the circulation, and affects
distant organ systems; in this regard, IL-I acts as a hormone mediating the host
responses to infection and inflammation. The primary sources of IL-I are blood
monocytes, phagocytic lining cells of the liver and spleen, and other tissue macro-
phages [2]; specialized cells such as B cells, large granular lymphocytes, keratinocytes,
gingival and corneal epithelial cells, renal mesangial cells, brain astrocytes and
microglia, and synovial lining cells also produce IL-1. The IL-I produced by these
latter cell types probably exerts its primary effects within tissues, and the production of
IL-I by strategically located, specialized cells participates in the mechanism of many
disease processes. This situation is particularly the case in the destructive aspects of
joint and bone disease. The impact of an IL-I mediated disease in a closed space is
probably underestimated until considerable damage has taken place or indications of
organ failure develop. Several investigators have found polypeptide inhibitors of IL-I
activity in plasma, urine, andjoint and peritoneal fluid, and it is speculated that these
naturally occurring substances play a role in abrogating IL-I effects.
Multiple Biological Activities ofIL-I
It is now clear that there is more than one IL-I gene from macrophagic cells, and it
remains to be shown whether IL-I produced from specialized cells like keratinocytes,
mesangialcells, and thelike, is related to themacrophage IL-I family [2]. IL-I is more
than just an interleukin since, in addition to its effects on neutrophils, T cells, B cells,
and natural killer cells, it affects several non-leukocytic targets such as the liver,
pancreas, bone, cartilage, muscle, synovial fibroblasts, and brain. IL-I is a family of
polypeptides affecting several unrelated tissues, while IL-2 is a single substance with
seemingly a single purpose. IL-1, to make a broad analogy, is similar to the family of
interferons in that there are multiple forms which retain a common biological property
(in the case ofinterferons, this is antiviral activity, and in the case ofIL-I this seems to
belymphocyte activation in the presenceofantigen or mitogen). Macrophageproducts
with various IL-I properties had been described for many years underdifferent names.
In addition to LAF, initial descriptions included endogenous pyrogen (EP), the
mediator of fever [3], and leukocytic endogenous mediator (LEM), the inducer of
hepatic acute-phase protein synthesis, neutrophilia, and changes in plasma divalent
cations [4]. Since then, other macrophage factors have been isolated and described,
such as mononuclear cell factor (MCF), which stimulates prostaglandin synthesis and
collagenase production in synovial fibroblasts [5]. The relationship of these various
biological activities has been recently reviewed [6]. Catabolin, a familyofpolypeptides
purified from pig blood monocytes, has now been shown to be an interluekin-I [7]
98INTERLEUKIN-1 AND TUMOR KILLING
From over 20 years ofinvestigation, considerable evidence supported the concept that
thesesubstances werephysically related [6]. Theapplications ofmolecular biologyand
recombinant DNA technology have begun to untangle how the IL-1 family is
structurally related and how the biological activities are segregated.
At the onset ofinfection or injury, blood monocytes and tissue macrophages become
activated either by phagocytosis ofthe invading microbe or by tissue products. Either
process results in the synthesis and releaseofIL-1. Although local effects ofIL-I in the
surrounding tissues contribute to certain acute pathological changes such as cellular
infiltration and hyperemia, IL-I also enters the circulation, where it stimulates several
distant tissue targets. These include fever and an increase in the number and
immaturity ofcirculating neutrophils. The release of neutrophils is apparently due to
the direct action of IL-I on the bone marrow [4]. There is a rapid drop in plasma iron
thought to be due, in part, to sequestration of iron in lactoferrin complexes, and
hypozincemia is present and thought to be mediated by hepatic metallothionein [8].
Muscle proteolysis and negative nitrogen balance occur via IL-I mediated increases in
prostaglandin E2 production [9]. In addition to the direct effect of IL-1 on muscle
tissue, there is an indirect effect on muscle as PGE2 production and muscledegradation
are enhanced at febrile temperatures. While the muscles arereleasing amino acids into
the circulation, hepatic uptake is increased, and there is a dramatic increase in hepatic
acute-phase reactants; however, albumin synthesis is reduced [10]. Acute-phase
proteins include those normal serum proteins whose concentrations increase several-
fold: such proteins as haptoglobin, certain protease inhibitors, complement compo-
nents, ceruloplasmin and fibrinogen, and those which increase several hundredfold.
The latter are true acute-phase reactants and include serum amyloid A protein, which
is a precursor of the amyloid fibril deposited in tissues of patients with secondary
amyloidosis, and C-reactive protein, which may serve several different nonspecific host
defense functions [10]. Although hepatic acute-phase protein synthesis may be under
the modulating control ofhomeostatic hormones, IL-I is clearly involved in triggering
the transcription and synthesis of these proteins [11,12]. Concentrations of these
proteins increase so that the sedimentation rates of erythrocytes reach very high
levels.
Several systemic changes contribute to the metabolic derangements seen during an
acute infection. There are increases in the production of insulin, glucagon, growth
hormone, TSH, and vasopressin which are probably influenced by circulating levels of
IL-1 [13]. The metabolic changes of the acute-phase response are clearly inefficient,
since amino acids from degraded muscle tissue are used for gluconeogenesis and
energy, while utilization of fat is reduced. The mechanism of metabolic catabolism
during infection and inflammation isdistinct from thatofstarvation [14]. Amino acids
arerequired for theproliferationoflymphocytes and fibroblasts as well as thesynthesis
of hepatic acute-phase reactants, immunoglobulins, and collagen for repairing dam-
aged tissues. The well-coordinated events of providing ample amino acids for these
cellularfunctions seems tobeorchestratedby IL-1. Theneed for an increasedsupplyof
energy substrates and a large supply ofamino acids for synthesis ofnew protein comes
at a time when food intake may be severely impaired or appetite reduced. IL-I
depresses appetite in experimental models [15]. Another systemic effect of IL-I is its
ability to induce slow wave sleep following intracerebroventricular or intravenous
administration [16], and there is a strong clinical impression that infection is
associated with increased sleep. There is also some speculation that the increased sleep
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may have an adaptive function in helping the host reserve its energies for fighting
infections [17].
IL-I stimulationoflymphocytes is avital hostdefensefunction sincethis contributes
to the initiation of cellular and humoral immune mechanisms directed against the
infecting microbe. There is a large body ofevidence concerning the functional role of
IL-1 for B-cell proliferation and antibody production [22,23] as well as for its role in
T-cell activation [24]. The importance of IL-1 for T cells involves the production of
lymphokines, the most notablebeing IL-2which, in turn, provides thegrowthsignal for
clonal expansion of various helper, suppressor, and cytolytic T cells and augments
natural killer cell activity [25].
Recombinant IL-is
The resolution of the present dilemma of how many of the multiple biological
activities of IL-I are, in fact, due to a single substance has begun with the cloning of
cDNAs coding for the human monocyte-derived [26] and the murine macrophage-
derived [27]. A similar dilemma had existed with the interferons (IFN), initially
described as antiviral substances, and serves as an analogy. Alpha (leukocyte)-IFN
had other biological properties including fever [28] and increased natural killer
activity, and recombinant IFNs have enabled investigators to confirm that IFNs
possess more properties than antiviral activity, such as increasing macrophage killing
and antigen expression. Recombinant human IL-2 also has biological properties other
than its ability to stimulate T-cell proliferation [29]. However, IL-I is unique in that
there is no signal or cleavage peptide sequence. As a result, most of the IL-I which is
.translated following stimulation remains intracellular [30], and the amount of IL-1
released into the surrounding medium is dependent on the type of stimulus. Other
workers have proposed that IL-I is bound to the surface ofmacrophages [31], and the
lack ofa signal peptide would certainly be consistent with this finding.
There seems little doubt that human IL-I is a family ofpolypeptides. Exactly how
many different genes code for human IL-I activity remains to be established.
Presently, there seem to be, at a minimum, two distinct IL-Is from human monocytes
[32], probably based on the two major isoelectric points of the molecule. The cDNA
made to the poly-A mRNA of the pI 7 codes for less than 26 percent amino acid
homology with the cDNA from the pl 5 form. Because of the lack of significant
homologies and based on restriction enzyme analyses, these two cDNAs probably
represent two distinct gene products. Others have suggested that three forms exist,
based on cDNA sequences which correspond to the three pIs. No nomenclature
presently exists for IL-1 but it seems logical to assign these forms by (a) species of
origin, (b) cell source, and (c) pl (or other physical characteristic) until more
information is known.
In studying the effects of IL-I on NK activity or on IL-I tumor lysis, it is necessary
to used purified preparations or recombinant IL-Is. Our initial studies [25] in IL-1
induced changes in NK activity were carried out using highly purified human
monocyte IL-1. Recent studies have also employed homogeneous human monocyte
IL-1 with a pI of 7 [33]. We have recently used in situ labeling of human monocytes
and purified the supernatant medium by immunoabsorption, gel filtration, and
chromatofocusing [34]. Three homogeneous bands at 7, 6, and 5 corresponded on SDS
PAGE to molecular weights of 18, 20, and 22 kd, respectively, each with activity as
endogenous pyrogens and lymphocyte activation. Using antibodies to purified porcine
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IL-Is with different pIs, antibodies raised to one pl form do not cross-react with the
other within the same species, whereas antibodies raised to the same pl form do
cross-react between the species [35]. This has also been shown with human IL-1 [36].
The IL-Is are presently defined biologically by their ability to augment mitogen- or
antigen-induced T-cell proliferation. Even using large amounts (Ag/ml) of purified
human recombinant IL-I with a pl of 7, no direct proliferative response was observed
on a cloned murine T helper cell line (D.10.G.4) or human peripheral blood T cells
unless in the presence of mitogens or antigens. In those incubations, IL-1 is active in
sub-nanogram/ml concentrations. The inflammatory property of the molecule is a
better indicator of its biological activity, since it is direct (that is, fever, PGE2
production, increased enzyme release and production). However, to solve the issue of
multiple biological activities, each IL-1 needs to be purified to homogeneity, free of
endotoxins, and the specific activity (biological units/mg protein) of each form
established in the multiple in vivo and in vitro assays. Both recombinant Escherichia
coli-derived and recombinant mammalian cell-derived IL-I will need to be evaluated,
since the recombinant bacterial products are not glycosylated. A critical aspect ofany
recombinant IL-1 study is the formidable problem of contaminating endotoxins.
Endotoxins are ubiquitous, and nanogram quantities can mimic IL-I in various assays.
The production of fever or endothelial neutrophil adherence are particularly sensitive
to endotoxins. Contaminating endotoxins from E. coli products present a unique
challenge in this regard.
IL-I and Tumor Killing
In vitro production of IL-I from human blood leukocytes of patients with various
diseases have demonstrated reduced IL-I production from circulating leukocytes of
malnourished patients and cancer patients with large tumor burdens [6]. Human
Epstein-Barr virus B-cell lines produce IL-1 [37], and this fact raises thespeculation of
IL-I in chronic viral diseases associated with immunosuppression. Although these data
are at present difficult to view in the context of IL-I as an enhancer of host defense
against malignancies, the direct effect of purified IL-I seems to enhance NK killing.
IL-I is known to synergize with IFN and IL-2 in increased tumor killing by NK cells
[25]. A recent report [38] has shown that purified pl 7 human monocyte IL-I has both
direct stimulatory effects on NK cells as well as acting as a direct anti-tumor factor for
certain tumor targets. There are also data which suggest that certain patients with
large tumor burdens produce less IL-I and that their NK tumor killing can be
normalized by the addition ofexogenous IL-1 [39]. Clearly, recombinant human IL-Is
provide the necessary materials to advance this important area ofclinical research. We
have recently expressed the human pl 7 IL-I and used it to study its effects on human
NK activity. The recombinant IL-I confirms previously published data on the ability
of IL-I to act synergistically with IL-2 and interferon-alpha [25].
Aspirin, acetaminophen, and non-steroidal anti-inflammatory agents are potent
inhibitors ofbrain prostaglandin synthesis and therefore are highly effective antipyre-
tics. These agents also reduce IL-I induced joint and muscle PGE2 synthesis, thus
helping alleviate the symptoms of arthritis and myalgia. Although non-steroidal
anti-inflammatory drugs reduce neutrophil chemotaxis, aggregation, and degranula-
tion caused by avariety ofinflammatory mediators, IL-I inducedneutrophil activation
appears unaffected by these drugs. Other aspects ofthe acute-phase response induced
by IL-1, such as release of neutrophils from the bone marrow, changes in serum
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divalent cations, and synthesis of acute-phase proteins, are also unaffected by
non-steroidal anti-inflammatory drugs. Furthermore, IL-1 mediated lymphocyte
activation is not diminished by these agents. Antipyretics do not reduce IL-1 induced
sleep [16], and this seems to be consistent with clinical observations that patients with
febrile diseases have increased sleep regardless of antipyretic therapy. There is,
however, increasing evidence that inhibitors of leukotriene synthesis block both IL-1
production and some of its biological activities [40,41]. Although there is a need to
develop IL-I antagonists, some effects of IL-I on the host play an important and vital
role in defenseagainst infection and malignant transformation and therefore, perhaps,
total antagonism is contraindicated. The role of acute-phase proteins in host defense
and repair is not entirely clear. Studies suggest that the major role of C-reactive
protein is to bind serum lipids or opsonize pneumococci, while serum amyloid A is
thought to beimmunosuppressive. Ceruloplasmin scavenges toxic free oxygen radicals
which are induced in neutrophils by IL-1. What is clear, however, is that the
production and physical structure of these acute-phase proteins has been conserved
through more than 600 million years ofevolution, and therefore they have presumably
been useful to the host. Reptiles and fish make an IL-I-like molecule, and an IL-I-like
substance has been isolated from starfish. This argues that IL-I and the acute-phase
response have played important roles in the survival of many species [42].
Fever and Tumor Killing
Before the development of radiation and chemotherapy, physicians depended upon
surgical excision as the primary treatment of most cancers. Infected surgical wounds
were not uncommon in the pre-antibiotic era, and in patients who developed post-
operative infections, tumorprogression and the advent of metastatic disease were often
delayed and, in some instances, prevented. This was particularly the case when wounds
were infected with erysipelas-producing strains of streptococci or gram-negative
organisms. Dr. William Coley, a New York City surgeon, had been sufficiently
impressed with this association that he routinely injected his post-operative patients
with a mixture of bacterial culture filtrates in an effort to induce the same type of
clinical responses that he had observed in infected patients.
Coley's toxins, a mixture of filtrates from erysipelas strains of Streptococci and
endotoxin-producing Serratiamarcescens, werewidely used before the introduction of
radiation therapy for cancer treatment. The immediate clinical response to the injec-
tion of these toxins was fever and, in many patients, hyperpyrexia (fever > 40.50C).
There is little doubt that Coley's toxins were occasionally effective, as several reports
have documented tumor regression and cures with toxin therapy [43-45]. Pyrogenic
endotoxins have been used in clinical trials in the United States, and a modified version
of Coley's toxin is currently being tested in Japan [46].
The mechanisms by which pyrogenic immunostimulants such as bacterial toxins
enhance host defenseagainstmalignant cells are unclear, but three possible effects are
probably involved: (1) the direct effect ofhyperthermia on the neoplastic cell growth,
(2) the effect of elevated temperature on the cells primarily concerned with host
defense, and (3) the ability of the pyrogenic immunostimulants to initiate the
production of various cytokines (sometimes called biological response modifiers),
which regulate host defense functions, particularly against malignant cells. Elevated
temperature has been shown to retard theproliferation ofcertain tumor cells both in
vitro [47] and in vivo [48], and tumorantigenexpression and cell membrane viscosity
are altered by temperatures in the febrile range (38.5-400C) [49].
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TABLE 1
Effects of Febrile Temperature on
Tumor-Killing Mechanisms
Increased at Elevated Temperatures
IL-I induced PGE production
Helper T-cell activation
Thymocyte mitogen responses
Antibody production in vitro
Antibody production in vivo
Generation ofcytotoxic T cells
Lymphocyte proliferation to viruses
Cytotoxic T-cell mediated killing





Natural killer cell activity
Another possible effect ofthe fever induced by these immunostimulants is the direct
effect oftemperature on cells primarily responsible for various host defense functions,
namely neutrophils, macrophages, and lymphocytes. Several studies have shown that
cellular functions increase at febrile temperatures (reviewed in [1] and [50]). Recent
studies have demonstrated enhanced effects of interleukin-1 (IL-1) on T cells at
elevated temperatures [51-55]. Elevated temperature also increases the generation
and killing efficiency of specific cytotoxic T lymphocytes. Thus, many components of
the host's response to biological response modifiers seem to be enhanced by the
elevated temperature (fever) which often accompanies its use. However, another host
defense function, namely natural killer (NK) activity [56-59], is apparently decreased
by elevated temperatures.
We examined the NK activity of human mononuclear cells following an 18-hour
incubation at 34, 37, and 390C in the presence ofIL-1, interleukin-2 (IL-2), and alpha
interferon (IFN). IL-1, IL-2, and alpha IFN or combinations ofthese mediators have
been previously shown tostimulate NK cell activity [25]. Inclinical trialsusing IFN or
IL-2 in patients with various malignant diseases, the most noted side effect is fever.
Homogeneous IL-1, studied experimentally as a potent pyrogenic substance, has yet to
be used clinically; however, culture supernates ofcertain human cell lines which have
been injected into humans contain large amounts of IL-I and have produced dramatic
pyrogenic reactions. Data derived from in vitro cultures have clearly established that
Coley's toxins and other pyrogenic immunostimulants are potent inducers of IL-I and
IFN production.
We therefore studied NK activity following exposure to IL-1, IL-2, and IFN at
various temperatures in order to mimic the effects of these cytokines on NK activity
during a febrile response. The production of IL-1, IL-2, burst promoting activity
(BPA), and granulocyte-macrophage colony-stimulating activity (GM-CSA) by
human peripheral blood mononuclear cells in vitro was also examined at these same
temperatures. In contrast to other immune functions that are enhanced at elevated
temperatures, we found that cytokine production and both baseline and cytokine-
primed NK activity are markedly inhibited at febrile temperatures (390C). Since
cytokine production and NK activity are closely associated with host defense against
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malignancy, these observations suggest that any benefit derived from exogenous IL-I
or IL-I induced byvarious toxin therapies takes placedespite the detrimental effects of
elevated temperatures. These studies support the concept that fever resulting from the
injection of an immunostimulant may partially negate any beneficial effects on
NK-directed tumor lysis and should be suppressed for optimal clinical results. Table 1
summarizes some effects of elevated temperature on mechanisms involved with
host-mediated tumor killing.
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